419 related articles for article (PubMed ID: 36601125)
1. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease.
Tao P; Ji J; Wang Q; Cui M; Cao M; Xu Y
Front Immunol; 2022; 13():1080456. PubMed ID: 36601125
[TBL] [Abstract][Full Text] [Related]
2. The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease.
Zhong C; Dai Z; Chai L; Wu L; Li J; Guo W; Zhang J; Zhang Q; Xue C; Lin H; Luo Q; Cai K
J Clin Lab Anal; 2021 Dec; 35(12):e24062. PubMed ID: 34689373
[TBL] [Abstract][Full Text] [Related]
3. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
Zaky A; Glastras SJ; Wong MYW; Pollock CA; Saad S
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502562
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.
Mao ZH; Gao ZX; Liu DW; Liu ZS; Wu P
Front Immunol; 2023; 14():1124704. PubMed ID: 36742307
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in
Yan H; Zhang Y; Lin X; Huang J; Zhang F; Chen C; Ren H; Zheng S; Yang J; Hui S
Int J Food Sci Nutr; 2024 May; 75(3):264-276. PubMed ID: 38238900
[TBL] [Abstract][Full Text] [Related]
6. A graminan type fructan from Achyranthes bidentata prevents the kidney injury in diabetic mice by regulating gut microbiota.
Si H; Chen Y; Hu D; Yao S; Yang J; Wen X
Carbohydr Polym; 2024 Sep; 339():122275. PubMed ID: 38823933
[TBL] [Abstract][Full Text] [Related]
7. Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis.
Li L; Wei T; Liu S; Wang C; Zhao M; Feng Y; Ma L; Lu Y; Fu P; Liu J
J Cell Mol Med; 2021 Jan; 25(2):960-974. PubMed ID: 33280239
[TBL] [Abstract][Full Text] [Related]
8. Roles of Gut Microbial Metabolites in Diabetic Kidney Disease.
Fang Q; Liu N; Zheng B; Guo F; Zeng X; Huang X; Ouyang D
Front Endocrinol (Lausanne); 2021; 12():636175. PubMed ID: 34093430
[TBL] [Abstract][Full Text] [Related]
9. Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease.
Drake AM; Coughlan MT; Christophersen CT; Snelson M
Nutrients; 2022 Oct; 14(21):. PubMed ID: 36364808
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota-derived short-chain fatty acids and kidney diseases.
Li L; Ma L; Fu P
Drug Des Devel Ther; 2017; 11():3531-3542. PubMed ID: 29270002
[TBL] [Abstract][Full Text] [Related]
11. Tangshen Formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism.
Chen DQ; Zhang HJ; Zhang W; Feng K; Liu H; Zhao HL; Li P
Exp Gerontol; 2024 Apr; 188():112393. PubMed ID: 38458480
[TBL] [Abstract][Full Text] [Related]
12. The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease.
Ma L; Zhang L; Li J; Zhang X; Xie Y; Li X; Yang B; Yang H
Mol Med; 2023 Oct; 29(1):148. PubMed ID: 37907885
[TBL] [Abstract][Full Text] [Related]
13. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression.
Mosterd CM; Kanbay M; van den Born BJH; van Raalte DH; Rampanelli E
Best Pract Res Clin Endocrinol Metab; 2021 May; 35(3):101484. PubMed ID: 33546983
[TBL] [Abstract][Full Text] [Related]
14. Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.
Wu XQ; Zhao L; Zhao YL; He XY; Zou L; Zhao YY; Li X
Pharm Biol; 2024 Dec; 62(1):423-435. PubMed ID: 38757785
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice.
Wang P; Guo R; Bai X; Cui W; Zhang Y; Li H; Shang J; Zhao Z
Front Endocrinol (Lausanne); 2022; 13():1034818. PubMed ID: 36589853
[TBL] [Abstract][Full Text] [Related]
16. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
[TBL] [Abstract][Full Text] [Related]
17. The Intestinal Microbiota Composition in Early and Late Stages of Diabetic Kidney Disease.
Zhang L; Lu QY; Wu H; Cheng YL; Kang J; Xu ZG
Microbiol Spectr; 2023 Aug; 11(4):e0038223. PubMed ID: 37341590
[TBL] [Abstract][Full Text] [Related]
18. Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective.
Das S; Gnanasambandan R
Life Sci; 2023 Mar; 316():121414. PubMed ID: 36682521
[TBL] [Abstract][Full Text] [Related]
19. Outer membrane vesicles derived from gut microbiota mediate tubulointerstitial inflammation: a potential new mechanism for diabetic kidney disease.
Chen PP; Zhang JX; Li XQ; Li L; Wu QY; Liu L; Wang GH; Ruan XZ; Ma KL
Theranostics; 2023; 13(12):3988-4003. PubMed ID: 37554279
[No Abstract] [Full Text] [Related]
20. Tangshen formula modulates gut Microbiota and reduces gut-derived toxins in diabetic nephropathy rats.
Zhao T; Zhang H; Yin X; Zhao H; Ma L; Yan M; Peng L; Wang Q; Dong X; Li P
Biomed Pharmacother; 2020 Sep; 129():110325. PubMed ID: 32535383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
